Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederroche.com
Roche Media News
Get the latest updates from Roche Media News directly as they happen.
Follow now 321 followers
Latest posts
Last updated 1 day ago
Roche data at ESMO 2025 showcase advances in science and cancer care across multiple tumour types
1 day ago
Basel, 13 October 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced...
Roche receives CE Mark for AI-based Kidney Klinrisk Algorithm(1) and launches new comprehensive chronic kidney disease (CKD) algorithm panel
8 days ago
Roche, in collaboration with KlinRisk, Inc, has received CE-mark for the first...
FDA approves Roche’s Tecentriq plus lurbinectedin as first-line maintenance therapy for extensive-stage small cell lung cancer
11 days ago
Combination reduced the risk of disease progression or death by 46% and...
Change in the Roche Board of Directors
11 days ago
Basel, 3 October 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced...
Roche commences tender offer for all shares of 89bio, Inc. for $14.50 per share in cash, plus a non-tradeable contingent value right for up to $6.00 per share in cash
12 days ago
Basel, 1 October 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced...
Data show Roche’s sixth-generation Troponin T test offers a new level of accuracy critical for diagnosing heart attacks
14 days ago
Recently granted CE Mark, the novel test delivers improved sensitivity and accuracy...
Roche presents new data for OCREVUS and fenebrutinib across broad patient populations at ECTRIMS 2025
20 days ago
OCREVUS subcutaneous maintains consistent benefit-risk profile after two years New late-breaking data...
Positive phase III results show Roche’s giredestrant significantly improved progression-free survival in ER-positive advanced breast cancer
22 days ago
evERA met its co-primary endpoints; giredestrant plus everolimus demonstrated significant benefit in...
CHMP recommends EU approval of Roche’s subcutaneous formulation of Lunsumio for people with relapsed or refractory follicular lymphoma
25 days ago
Lunsumio provides high and long-lasting response rates, with approximately two-thirds of patients...
Roche enters into a definitive merger agreement to acquire 89bio, and its phase 3 FGF21 analog for the therapy of moderate to severe MASH
26 days ago
89bio’s pegozafermin allows for a potentially best-in-disease treatment for moderate to severe...
New data for Roche's Vabysmo reinforce its efficacy, safety and durability in neovascular or “wet” age-related macular degeneration (nAMD)
about 1 month ago
In AVONELLE-X, the largest long-term extension trial in nAMD, disease control and...
Roche receives CE mark for Contivue, its Port Delivery Platform containing Susvimo, for neovascular age-related macular degeneration (nAMD)
about 1 month ago
Susvimo is under review with the EMA and once approved will be...